(Press-News.org) Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, despite no prior treatment with this therapy, according to recent results from a large multidatabase analysis.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR)
Author: Hao Xie, MD, PhD, a medical oncologist at Mayo Clinic Comprehensive Cancer Center
Background: “The KRAS pathway plays a crucial role in cell biology by regulating cell growth, proliferation, differentiation, and survival,” said Xie. “While KRAS signaling is tightly regulated in normal cells, mutations that lead to constantly active signaling, such as KRAS G12C, can lead to cancer progression. Such KRAS mutations are major drivers in many types of cancers, and are also linked to poor prognosis and chemotherapy resistance.”
The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma cases, according to Xie.
KRAS G12C inhibitors like sotorasib (Lumakras) and adagrasib (Krazati) have been effective for some patients whose cancers harbor this mutation, but many patients’ cancers are resistant to therapy even though they had no prior exposure to KRAS G12C inhibitors.
How the Study was Conducted: By analyzing circulating tumor DNA data from a total of 14,344 colorectal cancer patients and 5,438 pancreatic ductal adenocarcinoma patients from four different cohorts, Xie’s team sought to identify co-occurring genetic alterations that might be responsible for primary resistance to KRAS G12C inhibitors in these cancers.
Results: In patients whose cancers possessed the KRAS G12C mutation, the researchers identified co-occurring alterations with resistance potential in 46.5% of a national colorectal cancer cohort, 16.4% of a national pancreatic ductal adenocarcinoma cohort, 53.8% of a Mayo Clinic colorectal cancer cohort, and 36.4% of a Mayo Clinic pancreatic ductal adenocarcinoma cohort.
The most frequent co-occurring alterations in all groups were other non-G12C KRAS alterations, which were observed in at least 35.4% of these patients’ cancers in every cohort. Beyond KRAS, patients with KRAS G12C-mutated colorectal cancers were most commonly characterized by alterations including both point mutations and amplifications of NRAS, BRAF, MAP2K1, and EGFR, whereas MYC amplifications were present in KRAS G12C-mutated tumors in both pancreatic cancer patient cohorts.
Most strikingly, patients with pancreatic cancer whose tumors possessed KRAS G12C and co-occurring mutations associated with resistance, including other non-G12C KRAS alterations, were found to have a four-month median overall survival, compared to 22 months for those whose pancreatic cancer had the KRAS G12C mutation but lacked other co-occurring mutations. Patients with pancreatic cancer whose tumors lacked the KRAS G12C mutation had a median overall survival of 25 months.
Author’s Comments: “These other co-occurring mutations associated with poor prognosis may serve as cellular adaptation and primary resistance mechanisms, and may explain the limited efficacy of KRAS G12C inhibitor monotherapy,” Xie said. “Their presence also indicates the higher level of tumor heterogeneity in colorectal and pancreatic cancers, and emphasizes the importance of sequencing tumors with the KRAS G12C mutation for co-occurring resistance alterations.”
“KRAS G12C inhibitors are very promising, but they are not a panacea for these types of cancers. Patients and their doctors need to be aware of the current limitations.”
Study Limitations: Limitations of the study include its retrospective nature and that tumor genetic data was acquired via liquid biopsy which has the advantage of reflecting tumor heterogeneity but may be limited by tumor DNA shedding.
Funding & Disclosures: This study was supported by the Mayo Clinic Norma Lee and Morton Funger Clinician Career Development Fund Award in Colon Cancer Research, the Mayo Clinic Center for Clinical and Translational Science and Center for Biomedical Discovery Pilot Awards for Team Science, a Mayo Clinic Clinical and Translational Science Award from the National Center for Advancing Translational Sciences, and the Mayo Clinic Department of Oncology FORIT Award. Xie declares no conflict of interest.
END
Certain genetic alterations may contribute to the primary resistance of colorectal and pancreatic cancers to KRAS G12C inhibitors
2025-03-03
ELSE PRESS RELEASES FROM THIS DATE:
Melting Antarctic ice sheets will slow Earth’s strongest ocean current
2025-03-03
Melting ice sheets are slowing the Antarctic Circumpolar Current (ACC), the world’s strongest ocean current, researchers have found.
This melting has implications for global climate indicators, including sea level rise, ocean warming and viability of marine ecosystems.
The researchers, from the University of Melbourne and NORCE Norway Research Centre, have shown the current slowing by around 20 per cent by 2050 in a high carbon emissions scenario.
This influx of fresh water into the Southern Ocean is expected to change ...
Hallucinogen use linked to 2.6-fold increase in risk of death for people needing emergency care
2025-03-03
People seeking emergency care for hallucinogen use were at 2.6-fold higher risk of death within 5 years than the general population, according to a new study published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241191.
The use of hallucinogens, such as ketamine, psychedelics, psilocybin, LSD, ayahuasca, and MDMA (Ecstasy), has rapidly increased since the mid-2010s, especially in Canada and the United States. In the US, the percentage of people reporting they used hallucinogens more than doubled from 3.8% in 2016 to 8.9% in 2021. “In Canada, an estimated 5.9% of people used a psychedelic ...
Pathogenicity threshold of SCA6 causative gene CACNA1A was identified
2025-03-03
Niigata, Japan - The Department of Neurology at Niigata University and National Center of Neurology and Psychiatry（NCNP） has identified pathogenic thresholds for the CAG repeat units (RU) of the CACNA1A gene that causes SCA6. They investigated the SCA6 causative gene in 2,768 patients. They carefully examined the relationship between RU, age of onset, and family history. First, in cases with 18 or fewer RU, the proportion of family history was low. For 19 or more RU, the proportion of family history ...
Mysterious interstellar icy objects
2025-03-03
Niigata, Japan - Organic molecules that serve as the building blocks of life are believed to form in space, but their exact formation sites and delivery mechanisms to planets remain a major mystery in astronomy and planetary science. One of the key elements in solving this mystery is the presence of ice in interstellar environments. In cold, dense, and shielded regions of the galaxy, atoms and molecules adhere to the surfaces of submicron-sized solid particles (dust), leading to the formation of interstellar ices. This process is similar to how snow forms in Earth’s clouds.
Astronomers from Niigata University and ...
Chronic diseases misdiagnosed as psychosomatic can lead to long term damage to physical and mental wellbeing, study finds
2025-03-03
A ‘chasm of misunderstanding and miscommunication’ is often experienced between clinicians and patients, leading to autoimmune diseases such as lupus and vasculitis being wrongly diagnosed as psychiatric or psychosomatic conditions, with a profound and lasting impact on patients, researchers have found.
A study involving over 3,000 participants – both patients and clinicians – found that these misdiagnoses (sometimes termed “in your head” by patients) were often associated with long term impacts on patients’ physical health and wellbeing and damaged trust in healthcare services.
The researchers are calling for greater awareness ...
Omalizumab treats multi-food allergy better than oral immunotherapy
2025-03-02
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens. OIT, the most common approach to treating food allergy in the United States, involves eating gradually increasing doses of a food allergen to reduce the allergic response to it. Thirty-six percent of study participants who received an extended course of omalizumab could tolerate 2 grams or more of peanut protein, or about eight peanuts, and two other ...
Sleep apnea linked to increased risk of Parkinson’s, but CPAP may reduce risk
2025-03-02
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, SUNDAY, MARCH 2, 2025
Media Contacts:
Renee Tessman, rtessman@aan.com, (612) 928-6137
Natalie Conrad, nconrad@aan.com, (612) 928-6164
Sleep apnea linked to increased risk of Parkinson’s, but CPAP may reduce risk
Risk reduced if treatment started within two years of diagnosis
MINNEAPOLIS – People with obstructive sleep apnea have an increased risk of Parkinson’s disease, but if started early enough, continuous positive airway pressure ...
New insights into drug addiction: The role of astrocytic G protein-coupled receptors
2025-03-02
A recent study published in Engineering delves into the complex mechanisms of drug addiction, highlighting the crucial role of astrocytic G protein-coupled receptors (GPCRs). This research offers fresh perspectives on understanding and potentially treating substance-use disorders (SUDs).
For a long time, neuroscience research on drug addiction mainly focused on neuronal mechanisms. However, emerging evidence shows that astrocytes, the most abundant glial cells in the central nervous system, also play a significant part. Astrocytes ...
Digital twin technology: Transforming road engineering and its lifecycle applications
2025-03-02
A recent study published in the journal Engineering delves into the potential of digital twin (DT) technology in revolutionizing road engineering and its lifecycle applications. As road infrastructure worldwide faces the challenge of digitalization, DT has emerged as a promising solution.
The research, conducted by a team of scholars from Tongji University and Harbin Institute of Technology (Shenzhen), systematically reviews DT-enabling technologies, including model creation, condition sensing, data processing, and interaction. The development of DT in road engineering has been ...
Next-generation AI and big data: Transforming crop breeding
2025-03-01
A new study published in Engineering explores how next-generation artificial intelligence (AI) and big data are revolutionizing crop breeding, with potential far-reaching implications for global food security.
Crop breeding has come a long way, evolving through distinct stages from domestication breeding to the current era of big data intelligent design breeding. The latest stage, “Breeding 4.0,” integrates biotechnology, big data, and AI. This convergence aims to achieve efficient, personalized breeding of new crop varieties, marking a significant shift from traditional “scientific” ...